{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:22:18Z","timestamp":1788985338921,"version":"build-2803163510"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273521, 82404148"],"award-info":[{"award-number":["82273521, 82404148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["YG2024LC06"],"award-info":[{"award-number":["YG2024LC06"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M752033"],"award-info":[{"award-number":["2024M752033"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease characterized by hyperkeratotic follicular papules, palmoplantar hyperkeratosis, and associated normal \u201cislands of unaffected skin\u201d. Its pathogenesis has not been fully elucidated, and treatment poses significant challenges. Conventional therapies include oral retinoids and topical emollients. In recent years, although biological agents have been used in treatment, they are associated with side effects such as an increased risk of infection, and some patients show no response to treatment, thus necessitating the exploration of new therapeutic approaches.This case represents the first reported use of a TYK2 inhibitor (deucravacitinib) for the treatment of PRP. The patient was a 39-year-old male who developed extensive erythema in December 2024. The erythema gradually increased and progressed to red punctate eruptions accompanied by mild desquamation, slight pruritus with a stinging sensation, and \u201cislands of unaffected skin\u201d. Initial treatment with topical dinoprostone and mometasone furoate cream was ineffective. In March 2025, the patient received deucravacitinib (6 mg daily) in combination with topical halometasone cream. At the 1-month follow-up, significant improvements were observed in erythema, desquamation, and pruritus. At the final 6-month follow-up, the skin lesions almost resolved, leaving only mild erythema and a small amount of desquamation. Both the disease severity and the patient\u2019s quality of life were significantly improved. This case suggests that deucravacitinib exhibits favorable efficacy and safety in the treatment of PRP. However, due to the low incidence of PRP, which makes large-scale controlled trials difficult, and the lack of recognized treatment guidelines, more clinical studies are needed in the future to further verify the potential of deucravacitinib in the treatment of PRP.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1752884","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:48:13Z","timestamp":1770187693000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Successful treatment of pityriasis rubra pilaris with deucravacitinib"],"prefix":"10.3389","volume":"17","author":[{"given":"Yixuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyao","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14761","article-title":"Pityriasis rubra pilaris: algorithms for diagnosis and treatment","volume":"32","author":"Roenneberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/life14080923","article-title":"Emerging role of biologic drugs targeting IL-17 and IL-23: pityriasis rubra pilaris","volume":"14","author":"Potestio","year":"2024","journal-title":"Life (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e14714","DOI":"10.1111\/dth.14714","article-title":"The beneficial effect of a PDE4 inhibitor in a patient with juvenile-onset intractable pityriasis rubra pilaris without CARD14 mutation","volume":"34","author":"Inoue","year":"2021","journal-title":"Dermatol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2050313X231160927","DOI":"10.1177\/2050313X231160927","article-title":"Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: A case report","volume":"11","author":"Saad","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S470170","article-title":"Tofacitinib for pityriasis rubra pilaris: A case report","volume":"17","author":"Tan","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18556","article-title":"COVID-19 induced pityriasis rubra pilaris: A superantigenic disease","volume":"37","author":"Aromolo","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13718","article-title":"Systemic therapies of pityriasis rubra pilaris: a systematic review","volume":"17","author":"Kromer","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.05.010","article-title":"Familial pityriasis rubra pilaris is caused by mutations in CARD14","volume":"91","author":"Fuchs-Telem","year":"2012","journal-title":"Am J Hum Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/24755303231201336","article-title":"Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis","volume":"8","author":"Kingston","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1752884\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:48:17Z","timestamp":1770187697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1752884\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":10,"alternative-id":["10.3389\/fimmu.2026.1752884"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1752884","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"article-number":"1752884"}}